By Owen Tucker-Smith
InMed shares rose after the pharmaceutical company reported positive results from a long-term study of its Alzheimer's drug.
Shares of the Vancouver, Canada, company were up 4.9% on Tuesday to $5.19. The stock is down more than 11% over the past three months but up almost 9% this year.
The company said groups treated with its INM-901 drug in a long-term study had experienced a reduction in neuroinflammation markers. This reduction was statistically significant, it said.
Eric Hsu, the company's senior vice president of preclinical research and development, said neuroinflammation is a promising target for researchers studying Alzheimer's, and that the results from the study indicate that INM-901 may lower neuroinflammation.
The company added it will continue to study the drug's potential role in Alzheimer's treatment, and it expects to complete another round of analyses in the coming weeks. InMed noted that preclinical behavioral studies of INM-901 have associated the drug with improvement in cognitive function, memory, locomotor activity, anxiety-based behavior and sound awareness.
Write to Owen Tucker-Smith at owen.tucker-smith@wsj.com
(END) Dow Jones Newswires
January 21, 2025 13:01 ET (18:01 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。